HomeInsightsResults

Mankind Pharma Ltd Quarterly Result

Mankind Pharma Ltd Quarterly Result

stocks purchased

₹ 0.0 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

0.0 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 22, 2024

Image

Mankind Pharma Ltd

NSE: MANKIND

Net Profit

₹ 658.88

Last updated on: Nov 22, 2024

Key Highlights

  • The revenue of Mankind Pharma Ltd for the Sep '24 is ₹ 3188 crore as compare to the Jun '24 revenue of ₹ 2997 crore. This represent the growth of 6.3570557%.
  • The ebitda of Mankind Pharma Ltd for the Sep '24 is ₹ 962.04 crore as compare to the Jun '24 ebitda of ₹ 786.27 crore. This represent the growth of 22.35491%.
  • The net profit of Mankind Pharma Ltd for the Sep '24 is ₹ 658.88 crore as compare to the Jun '24 net profit of ₹ 543.07 crore. This represent the growth of 21.32506%.

Results Analysis

Market Price of Mankind Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Mankind Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
21 Nov 20242552.6
19 Nov 20242568
18 Nov 20242599.95
14 Nov 20242606
13 Nov 20242530.95
12 Nov 20242628.35
11 Nov 20242646.05
08 Nov 20242658.9
07 Nov 20242726.45
06 Nov 20242750.1

Historical Revenue of Mankind Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Mankind Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Mankind Pharma Ltd

No data available

* All values are in crore

Mankind Pharma Ltd News Hub

News

Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs ...

Read more

13 Nov 202413:14

News

Mankind Pharma receives reaffirmation in credit rating from CRISIL

Mankind Pharma has received reaffirmation in credit ratings from CRISIL as under: Commerci...

Read more

06 Nov 202413:15

News

Mankind Pharma hits life high after Q2 PAT jumps 30% YoY to Rs 653 cr

Profit before tax was at Rs 849.32 crore in Q2 FY25, registering a growth of 32.5% from Rs...

Read more

06 Nov 202410:03

News

Mankind Pharma Ltd spurts 0.01%, up for fifth straight session

Mankind Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 26...

Read more

04 Nov 202413:00

News

Mankind Pharma Ltd spurts 3.89%

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs...

Read more

31 Oct 202413:05

News

Mankind Pharma to convene board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 5 November ...

Read more

25 Oct 202416:07

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

July 2024

PPT

Jan 2024

PPT

June 2023

TranscriptPPT

FAQ's For Mankind Pharma Ltd Quarterly Result

What is the EPS of Mankind Pharma Ltd stock?

The Earnings Per Share (EPS) of Mankind Pharma Ltd is 52.79. An EPS is the amount of net income attributed to each share of a common stock.

How is Mankind Pharma Ltd EPS calculated?

The EPS of Mankind Pharma Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Mankind Pharma Ltd report its EPS?

Mankind Pharma Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Mankind Pharma Ltd EPS?

Factors that influence the EPS of Mankind Pharma Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Mankind Pharma Ltd EPS growth indicate future performance?

Yes, consistent growth in Mankind Pharma Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*